Novartis multiple sclerosis drug cuts relapse rates by a third in pivotal trials
Novartis's multiple sclerosis treatment remibrutinib cut relapse rates by a third compared with a standard treatment in pivotal trials, STAT reports. STAT How much does a…
1 post ·